EHS
EHS

STAT Plus: U.K. health officials make a counteroffer to Vertex for its pricey cystic fibrosis drugs

Seeking to break a stalemate over pricey cystic fibrosis drugs, the U.K.’s National Health Service has offered Vertex Pharmaceuticals (VRTX) what it called the “largest ever financial commitment of its type” for the company’s medicines.

After more than two years of haggling, the NHS agreed to “expanded and immediate” access to a pair of existing drugs, Orkambi and Kalydeco, and a forthcoming medicine called Symdeco. The agency also committed to making a next-generation triple therapy available once it is licensed by the government.

Continue to STAT Plus to read the full story…

EHS
Back to top button